---
document_datetime: 2023-09-21 21:06:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/oncaspar-epar-all-authorised-presentations_en.pdf
document_name: oncaspar-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6443916
conversion_datetime: 2025-12-24 09:16:09.253279
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA(EU) number    | (Invented) name   | Strength   | Pharmaceutical form                        | Route of administration            | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|--------------------------------------------|------------------------------------|-----------------------|---------------------------|-------------|
| EU/1/15/1070/002 | Oncaspar          | 750 U/ml   | Powder for solution for injection/infusion | Intramuscular use, Intravenous use | vial (glass)          | 3750 U                    | 1 vial      |